Renaissance Technologies LLC Acquires 104,924 Shares of West Pharmaceutical Services, Inc. $WST

Renaissance Technologies LLC lifted its holdings in West Pharmaceutical Services, Inc. (NYSE:WST) by 100.2% during the 1st quarter, HoldingsChannel reports. The fund owned 209,660 shares of the medical instruments supplier’s stock after acquiring an additional 104,924 shares during the quarter. Renaissance Technologies LLC’s holdings in West Pharmaceutical Services were worth $52,549,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the business. Elyxium Wealth LLC acquired a new stake in West Pharmaceutical Services in the 4th quarter worth about $25,000. CYBER HORNET ETFs LLC acquired a new position in shares of West Pharmaceutical Services during the 2nd quarter worth approximately $25,000. Cornerstone Planning Group LLC grew its position in shares of West Pharmaceutical Services by 90.9% during the 1st quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 50 shares in the last quarter. Bayban bought a new position in shares of West Pharmaceutical Services during the fourth quarter worth approximately $27,000. Finally, Private Trust Co. NA increased its holdings in shares of West Pharmaceutical Services by 156.4% during the fourth quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier’s stock worth $28,000 after purchasing an additional 61 shares during the period. 93.90% of the stock is owned by institutional investors.

West Pharmaceutical Services Stock Up 0.1%

Shares of NYSE WST opened at $328.61 on Monday. The company has a market capitalization of $23.13 billion, a P/E ratio of 42.08, a price-to-earnings-growth ratio of 2.56 and a beta of 1.16. West Pharmaceutical Services, Inc. has a 52-week low of $223.83 and a 52-week high of $386.00. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.12 and a current ratio of 2.82. The company’s 50 day moving average price is $337.02 and its 200-day moving average price is $287.49.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share for the quarter, topping the consensus estimate of $2.08 by $0.29. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The company had revenue of $872.30 million during the quarter, compared to analysts’ expectations of $839.98 million. During the same period in the prior year, the company posted $1.84 earnings per share. West Pharmaceutical Services’s revenue for the quarter was up 13.8% compared to the same quarter last year. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Equities analysts forecast that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current year.

West Pharmaceutical Services Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th will be given a dividend of $0.22 per share. The ex-dividend date of this dividend is Wednesday, July 29th. This represents a $0.88 dividend on an annualized basis and a yield of 0.3%. West Pharmaceutical Services’s dividend payout ratio is 11.27%.

More West Pharmaceutical Services News

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: West posted a strong second quarter, with adjusted EPS of $2.37 and revenue of $872.3 million, both above expectations. The company also raised full-year 2026 EPS guidance and gave third-quarter guidance that topped consensus, which supports the longer-term outlook. West Reports Second-Quarter 2026 Results
• Positive Sentiment: Demand remains strong for high-value injectable drug components, including products tied to GLP-1 and biologics markets, which helped drive the beat and the higher outlook. Reuters article on raised forecast
• Neutral Sentiment: Investors may be taking profits after the stock’s sharp earnings-driven surge in the prior session, especially since there was no major new negative company announcement or filing behind today’s weakness. Quiver Quantitative article
• Neutral Sentiment: Recent insider sales from two executives may add a small overhang, but the activity is limited and does not appear to be the main driver of the stock’s move. Insider trading details

Wall Street Analyst Weigh In

Several brokerages have weighed in on WST. Evercore reaffirmed an “outperform” rating and issued a $410.00 price objective on shares of West Pharmaceutical Services in a report on Monday, July 6th. Wolfe Research began coverage on shares of West Pharmaceutical Services in a research report on Monday, June 1st. They set an “outperform” rating and a $375.00 price objective for the company. Zacks Research upgraded shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, May 13th. Morgan Stanley increased their price target on West Pharmaceutical Services from $325.00 to $365.00 and gave the company an “equal weight” rating in a research note on Thursday, July 9th. Finally, Weiss Ratings upgraded West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, April 27th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, West Pharmaceutical Services presently has a consensus rating of “Buy” and an average target price of $363.17.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.